-
Unlocking the Mindās Eye: How Huntingtonās Disease Changes How We See and Process the World
Latest News
-
Exciting new Huntingtin lowering tool described
Exciting new Huntingtin Lowering work from @SangamoTx and @CHDIfoundation using "Zinc Fingers" to shut down expression of the mutant Huntingtin gene. More details on this exciting new technique here.
-
Details emerge of first Huntingtonās disease gene therapy clinical trial
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a āsingle-shotā virus delivery system.
-
Fresh Updates from First Huntingtin Lowering Study Publication
Hot off the presses – New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
-
An Updated Trial Design for Roche's Huntingtin Lowering Trial
Roche announces an update to the GENERATION HD1 trial after reviewing the ASO open label extension study
-
When interrupting is good: genetic hiccups that protect against Huntington's disease
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
-
Huntington's disease therapeutics conference 2019 – Day 3
New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 2
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 1
HDBuzz reports from the annual Huntingtonās disease therapeutics conference in Palm Springs
-
Huntington's disease goes viral as UniQure inches ahead in gene therapy race
FDA grants āInvestigational New Drugā status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntingtonās Disease patients
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager